Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 27,500 shares, a drop of 57.0% from the February 28th total of 63,900 shares. Based on an average daily trading volume, of 284,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Oncotelic Therapeutics Price Performance

Shares of OTCMKTS OTLC traded down $0.00 during mid-day trading on Friday, reaching $0.07. The company had a trading volume of 76,720 shares, compared to its average volume of 147,587. The company has a 50-day moving average price of $0.04 and a two-hundred day moving average price of $0.03. The stock has a market cap of $27.95 million, a PE ratio of -6.88 and a beta of -0.25. The company has a current ratio of 0.01, a quick ratio of 0.01 and a debt-to-equity ratio of 0.28. Oncotelic Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.07.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.